Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Child
Hospitalization
Humans
Infant
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
Respiratory Tract Infections
Seasons
United States

authors with profiles

PEDRO PIEDRA
JULIE BOOM
LEILA SAHNI